BS_YEQVW4ND
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 75.68988173455979
- age_years
- 9.975
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2774 | Med | Medulloblastoma | 0.958 |
| 2 | MDT-AP-0385 | Med | Medulloblastoma | 0.945 |
| 3 | BS_52426AMF | low-grade glioma | — | 0.925 |
| 4 | MDT-AP-0226 | Med | Medulloblastoma | 0.923 |
| 5 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.918 |
| 6 | BS_55JW3HFM | Ganglioglioma | — | 0.913 |
| 7 | sclcM1201764A_S68.txt | — | cohortMD2 | 0.910 |
| 8 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.908 |
| 9 | SRR8518208 | — | D | 0.905 |
| 10 | BS_1TPWFSK6 | subependymal giant cell astrocytoma(SEGA) | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.458 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.403 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.393 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.389 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.366 | Idelalisib | — uncovered |
| COMPLEMENT | 0.358 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.357 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| MYOGENESIS | 0.336 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.333 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.322 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.318 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.316 | Idelalisib | — uncovered |
| APOPTOSIS | 0.313 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.312 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.291 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.289 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.285 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.283 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.249 | Inavolisib | — uncovered |